Attia Mai S, Ayman Fadwa, Attia Mohamed S, Yahya Galal, Zahra Mansour H, Khalil Magdi Mohamed Ibrahim, Diab Abdel Aziz A
Department of Zoology, Faculty of Science, Zagazig 44519, Egypt.
Department of Pharmaceutics, Faculty of Pharmacy, Zagazig 44519, Egypt.
World J Diabetes. 2024 Aug 15;15(8):1778-1792. doi: 10.4239/wjd.v15.i8.1778.
Type 2 diabetes is one of the most prevalent chronic diseases worldwide, significantly impacting patients' quality of life. Current treatment options like metformin (MET) effectively counteract hyperglycemia but fail to alleviate diabetes-associated complications such as retinopathy, neuropathy, nephropathy, hepatopathy, and cardiovascular diseases.
To propose the supplementation of cholecalciferol (CHO) and taurine (TAU) to enhance MET efficacy in controlling diabetes while minimizing the risk of associated complications.
The study involved sixty rats, including ten non-diabetic control rats and fifty experimental rats with type 2 diabetes induced by streptozotocin. The experimental rats were further subdivided into positive control and treatment subgroups. The four treatment groups were randomly allocated to a single MET treatment or MET combined with supplements either CHO, TAU, or both.
Diabetic rats exhibited elevated levels of glucose, insulin, Homeostasis Model Assessment of Insulin Resistance (HOMA-IR), glycated hemoglobin%, lipid markers, aspartate aminotransferase, and malondialdehyde, along with reduced levels of antioxidant enzymes (catalase and superoxide dismutase). The administration of CHO and TAU supplements alongside MET in diabetic rats led to a noticeable recovery of islet mass. The antioxidative, anti-inflammatory, and anti-apoptotic properties of the proposed combination therapy significantly ameliorated the aforementioned abnormalities.
The supplementation of CHO and TAU with MET showed the potential to significantly improve metabolic parameters and protect against diabetic complications through its antioxidative, anti-inflammatory, and anti-apoptotic effects.
2型糖尿病是全球最普遍的慢性疾病之一，严重影响患者的生活质量。目前如二甲双胍（MET）等治疗方案能有效对抗高血糖，但无法缓解糖尿病相关并发症，如视网膜病变、神经病变、肾病、肝病和心血管疾病。
提出补充胆钙化醇（CHO）和牛磺酸（TAU）以增强MET控制糖尿病的疗效，同时将相关并发症风险降至最低。
该研究涉及60只大鼠，包括10只非糖尿病对照大鼠和50只通过链脲佐菌素诱导的2型糖尿病实验大鼠。实验大鼠进一步细分为阳性对照和治疗亚组。四个治疗组被随机分配接受单一MET治疗或MET与CHO、TAU或两者的补充剂联合治疗。
糖尿病大鼠的血糖、胰岛素、胰岛素抵抗稳态模型评估（HOMA-IR）、糖化血红蛋白百分比、脂质标志物、天冬氨酸转氨酶和丙二醛水平升高，同时抗氧化酶（过氧化氢酶和超氧化物歧化酶）水平降低。在糖尿病大鼠中，将CHO和TAU补充剂与MET一起给药导致胰岛质量明显恢复。所提出的联合治疗的抗氧化、抗炎和抗凋亡特性显著改善了上述异常情况。
CHO和TAU与MET联合补充显示出通过其抗氧化、抗炎和抗凋亡作用显著改善代谢参数并预防糖尿病并发症的潜力。
